LONDON (Alliance News) - Verona Pharma PLC said Thursday that a Phase 2a dose-finding trial of RPL554 in asthma has begun, with headline data expected in the first quarter of 2016.
The trial will include up to 30 patients with mild to chronic asthma, who will receive single doses of nebulised RPL554 from a very low dose to the highest dose it has previously tested.
"We have demonstrated in our previous studies in healthy volunteers with RPL554 in its new formulation that the drug is well tolerated at significantly higher doses than have previously been shown to produce bronchodilation. We have now begun examining the safety and bronchodilator responses to RPL554 in Chronic Obstructive Pulmonary Disease, in the ongoing Phase 1b study, and in asthma patients using our new formulation," said Chief Executive Officer Jan-Anders Karlsson in a statement.
Shares in Verona Pharma are trading up 3.3% at 5.68 pence Thursday morning.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.